Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 6/20 | 0.55 |
| ▸ | ABL1 | P00519 | 6/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818570 | 0.88 | CDK1 (0.55) | KDRKITFLT3CDK1CDK2 | |
| SCHEMBL2816963 | 0.87 | CDK1 (0.61) | KDRKITFLT3CDK1CDK2 | |
| SCHEMBL2819588 | 0.86 | ABL1 (0.51) | KDRKITFLT3ABL1BRAF | |
| SCHEMBL2818627 | 0.85 | FGFR4 (0.56) | KDRCDK1CDK2CDK8SRC | |
| SCHEMBL12973382 | 0.81 | FGFR4 (0.56) | KDRCDK1CDK2CDK8SRC | |
| SCHEMBL2819211 | 0.81 | KDR (0.53) | KDRKITFLT3CDK1CDK2 | |
| SCHEMBL2822262 | 0.78 | KDR (0.58) | KDRKITFLT3CDK1CDK2 | |
| SCHEMBL2817289 | 0.78 | KDR (0.60) | KDRKITFLT3CDK1CDK2 | |
| SCHEMBL14367013 | 0.78 | KDR (0.52) | KDRKITFLT3CDK1CDK2 | |
| SCHEMBL2816153 | 0.78 | KDR (0.68) | KDRKITFLT3CDK2CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061790-B1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | BAYER IP GMBH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1867648-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | KDR 1/4885KIT 18/4885FLT3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.